Theralase Technologies (TSE:TLT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Theralase Technologies has launched a new clinical study site at St. Joseph’s Healthcare Hamilton for its bladder cancer treatment using Ruvidar, achieving a complete response rate of over 61% in its Phase II trials. The company’s innovative anti-cancer therapy has shown promising results in treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, with a total response rate of over 68%.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
